4S Cost, Cost-Effectiveness, and Health-Economic Implications

At a glance

| Parameter | Detail | |---|---| | Trial | Scandinavian Simvastatin Survival Study (4S) | | N | 4,444 | | Intervention | Simvastatin 20 to 40 mg/day | | Comparator | Placebo | | Duration | Median 5.4 years | | Primary endpoint | All-cause mortality | | Key result | 30% relative risk reduction in all-cause mortality (RR 0.70 to 95% CI 0.58, 0.85, p = 0.0003) |

Why the 4S Economics Matter

When the 4S results landed in 1994, cardiologists had proof for the first time that lowering cholesterol with a statin could reduce deaths. But proof of efficacy does not automatically translate into prescribing behavior. Payers, formulary committees, and individual clinicians needed a second question answered: is the cost justified?

Simvastatin (marketed as Zocor by Merck) carried a brand-name price of roughly $1,200, $1,500 per year in the mid-1990s. For a drug prescribed indefinitely to millions of patients with prior myocardial infarction or stable angina, the aggregate budget impact was enormous. The economic analyses that followed 4S became a case study in how mortality data reshapes coverage decisions.

The Original Within-Trial Economic Analysis

Pedersen et al. published the primary 4S mortality data showing 256 deaths in the placebo group versus 182 in the simvastatin group over 5.4 years. But the trial also tracked hospitalizations, revascularization procedures, and days spent in hospital. These secondary data points became the foundation for the first cost-offset calculations.

Hospitalization Reductions

Simvastatin-treated patients had:

| Outcome | Simvastatin | Placebo | Relative reduction | |---|---|---|---| | Coronary revascularizations | 252 | 383 | 34% | | Hospital days (coronary causes) | ~4,600 | ~7,100 | ~35% | | Any cardiovascular hospitalization | Reduced |, | Significant |

These reductions mattered because coronary bypass surgery and balloon angioplasty were (and remain) among the most expensive procedures in cardiology. A single CABG in the early 1990s cost $30,000, $50,000. Avoiding even a modest fraction of those surgeries offsets years of drug costs.

Formal Cost-Effectiveness Models

The Jönsson et al. Swedish Analysis (1996)

One of the earliest formal economic evaluations came from Jönsson and colleagues, who used 4S data to model cost-effectiveness within the Swedish healthcare system. Their approach was straightforward: take the observed event rates from 4S, assign Swedish unit costs to each event, and calculate the incremental cost per life-year gained.

Key findings:

• Direct treatment costs were partially offset by savings from fewer hospitalizations and procedures.
• Cost per life-year gained ranged from approximately $3,800 to $9,400 (1996 USD equivalent), depending on the subgroup and modeling assumptions.
• For the highest-risk patients (older men with multiple risk factors), simvastatin was actually cost-saving, meaning it paid for itself entirely through avoided downstream care.

These numbers were remarkable. The commonly cited willingness-to-pay threshold was $50,000 per QALY even in the 1990s. Simvastatin came in at a fraction of that.

The Johannesson et al. Analysis (1997)

Johannesson and colleagues extended the economic modeling by incorporating quality-of-life adjustments and longer time horizons. They estimated:

| Subgroup | Cost per QALY (1996 USD) | |---|---| | Men 35, 59, baseline cholesterol >309 mg/dL | Cost-saving | | Men 35, 59, baseline cholesterol 213 to 309 mg/dL | ~$3,800 | | Women 35, 59 | ~$10,500 | | Men 60, 70 | ~$6,200 | | Women 60, 70 | ~$9,800 |

The pattern was consistent: simvastatin was either cost-saving or well within accepted thresholds across every subgroup studied. For patients with the highest baseline cholesterol or greatest number of risk factors, treatment actually reduced total healthcare spending.

The Goldman et al. U.S. Modeling

Goldman and colleagues applied 4S data to U.S. cost structures, where procedure prices are substantially higher than in Scandinavia. The higher baseline cost of revascularization and coronary care in the American system amplified the cost-offset effect. Even at Zocor's branded price, the cost per life-year gained remained under $15,000 for most secondary-prevention populations.

How 4S Economics Changed Payer Behavior

Before 4S, many insurers placed statins behind prior-authorization barriers or restricted them to patients who had failed diet therapy for 6 to 12 months. The mortality data from 4S made that position difficult to defend.

Formulary Shifts (1994 to 1998)

Within two years of publication:

• Most U.S. managed-care plans moved simvastatin to preferred formulary tiers for secondary prevention.
• The UK's National Health Service began recommending statin therapy for post-MI patients, partly on the basis of 4S cost-effectiveness data.
• Australian and Canadian public payers expanded reimbursement criteria for statins in established CHD.

The economic argument was simple: denying a $1,200/year drug that prevents $30,000+ surgeries was indefensible once RCT-level evidence confirmed the clinical benefit.

The Generic Inflection Point

Simvastatin lost patent protection in 2006 (U.S.) and earlier in some international markets. Generic pricing dropped the annual cost to $48, $120 per year. This changed the cost-effectiveness ratio dramatically.

| Era | Annual drug cost | Cost per QALY (secondary prevention) | |---|---|---| | Brand-name (1994 to 2006) | $1,200, $1,500 | $3,800, $15,000 | | Early generic (2006 to 2010) | $200, $400 | Strongly cost-saving | | Mature generic (2010, present) | $48, $120 | Dominant (cheaper and more effective than no treatment) |

At current generic prices, there is essentially no economic argument against treating eligible patients. The drug costs less per month than a single blood draw to check lipid levels.

List Price vs. Net Price: The Brand-Era Reality

During Zocor's patent-protected years, the gap between list price and net price mattered significantly for economic modeling. Merck offered volume-based rebates to large PBMs and managed-care organizations, meaning the effective price for most insured patients was 15 to 30% below list.

However, uninsured patients and those in high-deductible plans paid closer to full price. This created a disparity: the population-level cost-effectiveness was excellent, but individual out-of-pocket burden could be substantial. Medicare Part D did not exist until 2006, and many older patients in the 4S age range (35, 70 at enrollment) faced significant gaps in prescription coverage.

This gap between population-level value and individual affordability is a recurring theme in cardiovascular pharmacoeconomics. The FDA-approved labeling for simvastatin lists its indications for secondary prevention, but the label says nothing about how to pay for it.

Limitations of the 4S Economic Analyses

Several methodological caveats apply to all 4S-derived cost-effectiveness models:

Trial population was narrow. The 4S enrolled predominantly white Scandinavian men (81% male) aged 35, 70 with established CHD and total cholesterol 213 to 309 mg/dL. Extrapolating cost-effectiveness to populations not represented in the trial (different ethnicities, lower baseline risk, very elderly) requires assumptions that may not hold.

Costs were modeled, not directly measured. The trial itself did not prospectively collect cost data in a standardized format. Economic analyses applied unit costs retroactively to observed clinical events. This approach is standard but introduces uncertainty, particularly when transferring results across healthcare systems with different pricing structures.

Time horizon limitations. Most models projected benefits over 5 to 10 years. Patients starting simvastatin at age 45 might take it for 30+ years. Long-term cost-effectiveness depends on whether the relative risk reduction observed in 4S persists, attenuates, or changes over decades. The extended follow-up data from 4S provided some reassurance but did not cover truly lifelong therapy.

Adverse event costs were underweighted. The 4S trial reported low rates of serious adverse events with simvastatin, but post-marketing surveillance later identified myopathy risk (particularly at 80 mg doses) and potential interactions with certain medications. Economic models built in the 1990s did not fully account for these downstream costs.

Discount rates change the math. Economists discount future health benefits to reflect time preference. At a 3% annual discount rate (standard in the U.S.), a death prevented 10 years from now is "worth" less than one prevented today. The choice of discount rate materially affects cost-per-QALY calculations.

The Relative-Value Calculation for Individual Patients

For a patient with established coronary disease considering whether to start simvastatin, the economic question in 2026 is almost trivially favorable. At generic prices of $4, $10 per month, the out-of-pocket cost is negligible. The clinical benefit, a 30% reduction in all-cause mortality over 5.4 years, represents one of the largest effect sizes seen in cardiovascular prevention trials.

The practical barriers to treatment in the current era are not economic. They are adherence, side-effect concerns (particularly muscle symptoms), and clinical inertia. Cost-effectiveness analyses from 4S helped remove the financial barrier. The remaining barriers require different solutions.

4S in Context: Comparison With Later Statin Economics

The economic case for statins expanded substantially after 4S. Subsequent trials studied different populations and drugs:

• WOSCOPS (1995) demonstrated pravastatin's benefit in primary prevention, where cost-effectiveness ratios are inherently higher because baseline event rates are lower.
• HPS (2002) showed simvastatin 40 mg reduced events across a broad range of baseline cholesterol levels, expanding the eligible population.
• JUPITER (2008) tested rosuvastatin in patients with elevated CRP but normal LDL, raising questions about whether treating low-risk populations is economically justified.
• ACC/AHA cholesterol guidelines (2018) incorporated risk-based thresholds that implicitly reflect cost-effectiveness considerations.

4S remains the benchmark because it showed the largest mortality effect in the highest-risk group, making the economic case straightforward. As statins moved into lower-risk populations, the cost-effectiveness arguments became more nuanced and contested.

The Bottom Line for Clinicians and Patients

Simvastatin for secondary prevention of CHD is, by any standard measure, one of the most cost-effective medical interventions available. This was true at brand-name pricing in the 1990s. At today's generic pricing, the value proposition is overwhelming. The economic analyses derived from 4S played a direct role in shifting payer behavior, expanding formulary access, and establishing the precedent that mortality-reducing drugs should not face restrictive coverage barriers.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389. PubMed
• Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J. 1996;17(7):1001-1007. PubMed
• Johannesson M, Jönsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336(5):332-336. PubMed
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Cholesterol Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. PubMed
• FDA Drug Label: Simvastatin (Zocor). FDA